CME Situation Room: Exploring the Cardiovascular and Neurocognitive Implications of CETP Inhibition

Friday, June 12, 2026 | 6:45 - 8:45 am

This continuing education activity is provided by the National Lipid Association.
Educational Partner: Vindico Medical Education

Many patients with dyslipidemia, particularly those at high cardiovascular (CV) risk, do not achieve recommended low-density lipoprotein cholesterol (LDL-C) targets, resulting in persistent residual risk. Updated guidelines highlight the need for more intensive and individualized lipid-lowering strategies, yet gaps remain in clinician knowledge regarding newer therapeutic approaches. Cholesteryl ester transfer protein (CETP) inhibition has re-emerged as a promising mechanism, with recent clinical data demonstrating reductions in LDL-C, apolipoprotein B (apoB), and lipoprotein(a) (Lp[a]) with a promising safety profile in high-risk populations. Additionally, emerging evidence suggests a potential link between lipid lowering and reduced neurocognitive risk. This live, case-based CME activity will review the latest evidence on CETP inhibition and engage learners through a unique CME Situation Room component to apply these data to clinical practice to optimize dyslipidemia management and improve patient outcomes.

This is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.

---

This activity is supported by an educational grant from NewAmsterdam Pharma B.V.